Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liberseal is a human plasma-derived topical fibrin sealant developed by the Scottish National Blood Transfusion Service (SNBTS). It is a biological combination product consisting of two primary active components: fibrinogen and thrombin. When applied to a surgical site, thrombin enzymatically converts fibrinogen into fibrin, creating a stable physiological clot that mimics the final step of the natural coagulation cascade. This mechanism promotes hemostasis, tissue sealing, and wound closure. Liberseal is currently being evaluated in Phase 3 clinical trials in the United Kingdom to assess its efficacy in promoting leg wound healing and reducing surgical wound complications, including infections, in patients undergoing elective coronary artery bypass grafting (CABG) with saphenous vein harvesting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fibrin sealant (Scottish National Blood Transfusion Service).